impact of disabling systemic diseases on implant rehabilitation has been described in systematic reviews (Beikler and Flemmig, 2003; Bornstein et al., 2009; Diz et al., 2013; Donos and Calciolari, 2014; Mombelli and Cionca, 2006; Scully et al., 2007) . These uncontrolled medical conditions may have an effect at the local or systemic level and have been associated with an increased risk of breakdown of the peri-implant tissues (Heitz-Mayfield & Huynh-Ba, 2009; HeitzMayfield, Needleman, Salvi & Pjetursson, 2014; Lang et al., 2011; Lang et al., 2004; Monje, Catena & Borgnakke, 2017) . Systemic diseases as obesity, arthritis, and other chronic diseases induce a lowgrade systemic inflammatory condition associated with high levels of circulating pro-inflammatory cytokines that favor the chemotaxis and activations of monocytes, neutrophils, and adipose tissue macrophages, which may ultimately contribute to the establishment of bone loss and peri-implant disease (Hill, Reid Bolus & Hasty, 2014; Straub et al., 2015; Wei, Tarling, McMillen, Tang & LeBoeuf, 2015) .
In addition to uncontrolled systemic diseases itself, the systemic intake of medication such as thiazide diuretics, β-blockers, anti-inflammatory drugs, proton pump inhibitors, or serotonin reuptake inhibitors have shown to further modulate bone metabolism (Abrahamsen and Vestergaard, 2013; Brater, 1998 Brater, , 2011 de Vernejoul et al., 2012; Geusens et al., 2013; Haney & Warden, 2008; Vestergaard, 2008; Wiens et al., 2006) . These medication-related side effects are less understood and may exert an important influence on implant-related outcomes. Therefore, in recent demographical trends with an aging population, a comprehensive assessment and understanding of the patient's medical background is important, as related medication-specific side effects are able to influence bone metabolism (Insua, Monje, Wang & Miron, 2017; Kremers et al., 2016) .
Osteocytes play a crucial role in bone turnover processes, such as osseointegration, and are a major source of receptor activator of nuclear factor-kappaB ligand (RANKL) in bone (O'Brien, Nakashima & Takayanagi, 2013) , which is required for osteoclast differentiation and activation (Kong et al., 1999) . Hence, in case of medicationinduced disruption of osteocyte metabolic activities, adequate peri-implant bone remodeling in early stages of healing may be jeopardized. Likewise, anti-hypertensive medications, such as betablockers or angiotensin-converting enzyme inhibitors, have been shown to inhibit the normal physiologic function of osteoclasts on bone by blocking surface β-2 adrenergic receptors, which may result in shifting the balance toward bone formation by blocking the reninangiotensin system (Brater, 1998 (Brater, , 2011 . Furthermore, the action of serum serotonin reuptake inhibitors (SSRIs) on certain receptors and serotonin transporters, such as 5-HT1B, 5-HT2B or 5-HT2C, may result in a direct detrimental effect on bone metabolism by increasing osteoclast differentiation (Haney & Warden, 2008; Vestergaard, 2008) , which may negatively impact the process of osseointegration.
A comprehensive assessment and understanding of the patient's medical background and current medications is important for lifelong implant-supported rehabilitations. Therefore, the aim of this systematic review was to investigate the association between the intake of medications that may affect bone metabolism and implant outcomes.
| MATERIAL AND ME THODS
This systematic review was conducted according to the guidelines of the Preferred Reporting Items of Systematic Reviews and Metaanalyses (PRISMA) statement (Moher, Liberati, Tetzlaff, Altman, & PRISMA Group, 2009 
| Eligibility criteria
Prospective or retrospective cohort, case-control, cross-sectional, or randomized controlled trials exploring the association of medication intake and implant failure in humans were considered for inclusion.
| Literature search protocol
Electronic and manual literature searches were conducted independently by two authors (AM, VC) in several databases, including Moreover, a less specific screening using non-MeSH index terms was conducted to ascertain the articles to be evaluated. The screen- On the other side, for the EMBASE Library, the key terms used were as follows: ('dental implant'/exp OR 'dental implants') OR ('endosseous implant' OR 'endosseous implants') AND ('medication-related'/ exp OR 'medications-related') OR 'drug-related'/exp OR 'drugsrelated' AND 'implant failure'/de AND 'human'/de AND 'article'/it. 
| Risk of bias
The methodological and reporting quality of all selected full-text reports was assessed according to the STROBE statement for observational studies (Shea et al. 2009; von Elm et al. 2007 ). Moreover, the Assessment of Multiple Systematic Reviews guidelines (AMSTAR) was followed (Shea et al. 2009 ).
| The Newcastle-Ottawa Scale for assessing the quality of non-randomized studies (NOS)
Assessment of the quality of non-randomized, non-interventional studies is essential for proper evaluation of the evidence provided by each study. We followed the Newcastle-Ottawa System (NOS) protocol (Wells et al. 2011) . The items evaluated were selection of study groups, comparability of participants, and outcome. Each included study received a maximum score of 13 points for cohort studies and 10 points for case-control studies (Table S1 ). The Cohen's kappa coefficient was calculated to assess inter-rater agreement (AM and GAO).
| Statistical analysis
The statistical analysis was performed with the statistical software package R 3.1.1 (The R Project for Statistical Computing, www.rproject.org). The feasibility of conducting specific quantitative analyses (meta-analyses) was explored. If feasible, the additional package "meta" was used. Meta-analyses for the binary outcome implant failure (IF) were performed. The numbers of implants in both experimental and control groups were extracted directly from the data; the numbers of failures had to be calculated from the reported failure rates. As aforementioned, studies with missing information were excluded from the quantitative analysis.
The odds ratio of failure in the test group (individuals in-taking medications) vs. failure in the control group (individuals not taking any known relevant medication) was analyzed. Estimated odds ratios together with 95% confidence intervals were calculated for every included study as well as for the pooled set of studies. The studies were pooled using the inverse variance method. Both fixed and random weights were applied, yielding two different estimates of the population odds ratio. The heterogeneity among the included studies was measured computing I 2 and a p value for the null of homogeneous studies. This p value was compared to the level of significance of 5%.
| RE SULTS

| Study selection (Figure 1)
A total of 430 entries were identified through the electronic search, and after removal of duplicates. The initial pool was not supplemented with any further article identified through manual search or cross-reference assessments. Of these 430, forty articles were assessed for full-text evaluation, resulting in a final selection of 17 articles for qualitative assessment (Table 1) Zahid, Wang & Cohen, 2011) . A total of 23 articles did not meet the eligibility criteria and were subsequently excluded ( Table 2 ).
The studies included for qualitative assessment were pooled according to the medication category. As such, five studies were focused on evaluating the association of implant failure and non-steroidal antiinflammatory drugs (NSAIDs) (Alissa et al., 2009; Jeffcoat et al., 1995; Reddy et al., 1990; Urdaneta et al., 2011; Winnett et al., 2016) , two on selective serotonin reuptake inhibitors (SSRIs) (Chrcanovic et al., 2017b; Wu et al., 2014) , two on proton pump inhibitors (PPIs) (Chrcanovic et al., 2017a; Wu et al., 2017) , seven on oral bisphosphonates (BPs) (AlSabbagh et al., 2015; Famili et al., 2011; Grant et al., 2008; Koka et al., 2010; Memon et al., 2012; Siebert et al., 2015; Zahid et al., 2011) , and one on anti-hypertensives (AHTNs) (Wu et al., 2016) .
| Studies methods
With regard to research methodology, the vast majority of the included articles (12) were based on retrospective cohort studies (RC) (Chrcanovic et al., 2017a,b; Famili et al., 2011; Grant et al., 2008; Koka et al., 2010; Memon et al., 2012; Urdaneta et al., 2011; Winnett et al., 2016; Wu et al., 2014 Wu et al., , 2016 Wu et al., , 2017 Zahid et al., 2011) , three were randomized controlled trials (RCT) (Alissa et al., 2009; Jeffcoat et al., 1995; Reddy et al., 1990) , one prospective cohort (PC) (Siebert et al., 2015) , and one case-control (CC) (Al-Sabbagh et al., 2015) .
| Association of medication-related implant failure
Overall, five groups could be pooled according to the medication type. For hypertension-related medication-associated implant failure (i.e., beta-blockers or ACE inhibitors), only one study could be identified and accordingly, no subset meta-analysis could be car- No analysis was conducted for secondary outcomes. Implant survival (IS) was redundant to the primary outcome IF, whereas marginal bone loss (MBL) and timing of failure (TF) were reported in too few studies.
| Odds ratio for implant failure according to the medication intake
No subset meta-analysis could be conducted for AHTNs medications as only one study fulfilled the inclusion criteria, which revealed an increased survival rate of AHTN medication. For PPIs, the homogeneity of the two studies could not be rejected at the 5% level (I 2 =0, p = 0.78). Both the fixed effects and the random effects model estimate an odds ratio of a failure in the experimental group against a failure in the control group of 2.02. The corresponding 95% confidence interval does not contain 1.00, so there is a significant effect of the medication (p < .05) (Figure 2 ). Likewise, for SSRIs, the homogeneity of the two studies could be rejected at the 5% level (I 2 = 0, p = .36).
The fixed effects model estimated an odds ratio of IF in the experimental group against failure in the control group of 2.92; the random effects model resulted in 3.00 ( Figure 3 ). Thus, a significant effect of the experimental medication was found (p < .05). When analyzing oral BPs, one study (Al-Sabbagh et al., 2015) was excluded from the analysis due to missing IF in the control group, as previously mentioned.
For the remaining six studies, the homogeneity could not be rejected at the 5% level (I 2 = 27, p = .24). The fixed effects model estimated an odds ratio of failure in the experimental group against failure in the control group of 1.11, while the random effects model indicated an TA B L E 1 (additional columns -continued) odds ratio of 1.21. Hence, an effect of the experimental medication could not be concluded (p > .05 for the null of no effect) (Figure 4 ).
| Quality assessment
After the screening process, we found 13 studies included in the qualitative assessment that could be analyzed with NOS (Table S1) .
A Cohen's kappa inter-rater agreement rate of .92 was reached.
After discussing the disagreements between the examiners (AM and GAO), a mean NOS score of 6.38 ± 2.43 was obtained.
| D ISCUSS I ON
| Principal findings
Although survival in implant dentistry does not represent a challenge anymore, failures and complications still occur (Brugger et al., 2015) . The present systematic review revealed an insight into the possible effect of some medications on implant failure. Interestingly, PPIs used to reduce the production of acid by blocking the enzyme in the wall of the stomach that produces acid (Colmenares & Pappas, 2016) and SSRIs used for depression and anxiety conditions (Galli, Macaluso & Passeri, 2013) exhibited an increased risk of implant failures. On the other side, unexpectedly, the use of oral BPs for the treatment of osteoporosis did not yield significance when analyzing their impact on implant failure. This finding is of special interest as oral BPs intake was reported to be associated with a significantly higher risk to develop osteonecrosis of the jaw due to the blocking of osteoclastic activity (Edwards et al., 2007) . To the best of authors' knowledge, this systematic review was the first one in highlighting the potential implications of medications upon implant longevity.
Nevertheless, findings from this study cannot be conclusive due to the studies' design and consequently, the number of inherent uncontrolled confounders. Accordingly, it is encouraged to prospectively study the effect of these medications upon early and late implant failure controlling other known risk factors for the stability of the peri-implant tissues.
| Are our findings biologically plausible?
The effect and interaction of some medications with bone homeostasis has been extensively documented in preclinical studies (David, Nguyen, Barbier & Baron, 1996; Galli et al., 2013; Haney & Warden, 2008; Insua et al., 2017; Nyman, Schroeder & Lindhe, 1979; Robinson, Tashjian & Levine, 1975; Rzeszutek, Sarraf & Davies, 2003; Vestergaard, 2008) . Recently, in vivo clinical reports have been of great interest in the field of implant dentistry due to the likely role of these medications upon osseointegration (Winnett et al., 2016; Wu et al., 2014 Wu et al., , 2016 Wu et al., , 2017 . The present meta-analysis yielded statistical significance to feature the possible relevance of PPIs and SSRIs on IF.
Proton pump inhibitors aim at inhibiting the acid output to the stomach for the treatment of gastroesophageal reflux or gastric ulcers. The underlying mechanism that could negatively impact osseointegration leans on the impaired effective calcium uptake through the intestines (Kopic & Geibel, 2010 . Calcium is an essential mineral for the proper formation and maintenance of the skeleton as it may impact upon the bone mineral density (Tai, Leung, Grey, Reid & Bolland, 2015) . In point of fact, a calcium intake of at least 1,000-1,200 mg/day has been recommended to minimize the risk of osteoporosis (Tang, Brooks, Wetmore & Shireman, 2015) . O'Connell, Madden, Murray, Heaney and Kerzner (2005) examined for 7 days the intake of omeprazole 20 mg QD and found out a reduced calcium absorption when compared to a placebo medication in postmenopausal women. A further study confirmed that urine calcium excretion was reduced when in-taking omeprazole 20 mg TD (Graziani et al., 1995) . Hence, understanding the effect of PPIs on calcium reduction and the detrimental result upon bone homeostasis highlight the clinical implications of the intake of PPIs on IF.
Along the same lines, SSRIs used for depressive or anxiety conditions have been further identified to play a pivotal role on the osteoblast/osteoclast balance. As such, serotonin can regulate osteoclast activation and differentiation as osteoclasts derive from hematopoietic cell precursors (Battaglino et al., 2004) . As a matter of fact, the activity of the serotonin transporter and receptor is present in bone. Consequently, SSRIs have demonstrated to have detrimental effect on bone mineral density and trabecular microarchitecture through their anti-anabolic skeletal effects (Kahl et al., 2006) . For this reason, it might be hypothesized to negatively influence the process of osseointegration. Recently, a preclinical in vivo study has elucidated the effect of SSRIs on osteoblast differentiation and bone regeneration in rats. Interestingly, SSRI medication significantly reduced osteogenic differentiation and mineralization with concomitant reduction of osteoblast marker genes including alkaline phosphatase, Osterix, and osteocalcin, indicating its putative impact on the regulation of bone metabolism (Nam et al., 2016) .
Hence, such cellular findings would be in concordance with the results obtained by Wu et al. (2014) , who demonstrated that patients in-taking SSRIs experienced an increased risk of IF (hazard ratio: 6.28; 95% confidence interval: 1.25-31.61; p = .03). In addition, it should also be considered that the higher risk of implant failures may is influenced as well by the psychological condition of the patient rather than by the intake of SSRI.
On the other side, medications reported in the literature to possibly interfere with osseointegration or bone homeostasis such as NSAIDS or oral BPs have failed to show statistical significance.
As aforementioned, these findings must be cautiously interpreted, as there are other confounding factors such as the absence of an effect on implant survival due to the given dosages. The largest and longer term study analyzing failing osseointegration of 197 implants revealed that patients using NSAIDs peri-operatively experienced 44% IF, while 38% IF rate was occurred in patients, who did not take NSAID peri-operatively. Moreover, the NSAIDs cohort experienced 3.2 times more cases of radiographic bone loss >30% of the overall height and 1.9 times more cases of cluster failures (Winnett et al., 2016) . Accordingly, it might be speculated that the intake of peri-operative NSAIDs may inhibit the inflammatory bone metabolism, especially in vulnerable populations while having minimal clinical effect in healthy patient populations (Winnett et al., 2016) . In contrast, the use of AHTNs has been suggested to have a beneficial impact on implant longevity. The biological plausibility of this finding rests on the fact that AHTNs drugs can affect bone metabolism by inhibiting osteoclasts catabolic effects on bone by blocking their β2 adrenergic receptors (beta-bloquers), to enhance bone formation by increasing calcium absorption at the distal convoluted tubule (thiazides) or by shifting the balance toward bone formation by blocking the renin-angiotensin system (ACE inhibitors) (Wu et al., 2016) . In addition, oral BPs did not show to substantially contribute to IF. This is an interesting finding, as this medication mainly used for osteoporosis or cancer therapy is likely the most widely documented medication affecting the skeletal bone characteristics (Brufsky & Mathew, 2015; Rachner, Khosla & Hofbauer, 2011; Sambrook & Cooper, 2006) . Briefly, BPs inhibit the digestion of bone by promoting the apoptosis or cell death of osteoclast, thereupon decreasing the rate of bone resorption along the therapy (Migliorati, Siegel & Elting, 2006) . One of the most common complications in our field has been the increased risk of osteonecrosis of the jaw as a consequence of dental extraction or otherwise oral surgery (Ruggiero et al., 2009) . Authors want to reiterate that when interpreting these results must be exercised cautiousness due to the lack of homogeneity with regard to the dosage and timing in-taking oral BPs reported in the studies, but apparently seems not to represent a contraindication for implant therapy in osteoporotic patients. Contrarily, bone malignancies/ metastases involving the intake of intra-venous BPs represent an absolute contraindication for implant therapy.
| Limitations and future directions
The findings of the present study should be interpreted with great caution. First of all, due to the nature of the included study designs in the present systematic review, no "cause-effect" relationship can be established, but "association" and thus, findings from the present review encourage to investigate in a prospective manner the impact of medications on implant outcomes controlling other known confounders (i.e., smoking, plaque control, or other local and systemic contributing factors) that could potentially interfere in the implant stability. Moreover, the timing of implant failure must be adequately reported. In this sense, this would help to gain perspective on possible underlying mechanisms that elicit implant failure.
Along these lines, it is encouraged to investigate the effect of polymedication on osseointegration and implant failure. Furthermore, a major limitation that was found when investigating the biological complications was the lack of standardization with regard to the definition of peri-implant disease. Hence, it is strongly advised to follow the guidelines recommended by the European Federation of Periodontology and the American Academy of Periodontology to report on biological complications using clinical and radiographic assessments.
| CON CLUS IONS
Findings from the present systematic review showed an association of proton pump inhibitors and selective serotonin reuptake inhibitors with implant failure. Hence, the effect of these medications should be further investigated in future studies as potential confounders for implant outcomes.
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